Наша группа организует более 3000 глобальных конференций Ежегодные мероприятия в США, Европе и США. Азия при поддержке еще 1000 научных обществ и публикует более 700 Открытого доступа Журналы, в которых представлены более 50 000 выдающихся деятелей, авторитетных учёных, входящих в редколлегии.
Журналы открытого доступа набирают больше читателей и цитируемости
700 журналов и 15 000 000 читателей Каждый журнал получает более 25 000 читателей
Mayo Yoshimi
Disease status at allogeneic hematopoietic cell transplantation (HCT) is an important pretransplant prognostic factor of HCT in adult T cell leukemia/ carcinoma (ATL); still, other prognostic factors, including comorbidities, weren't prophetic in small cohort analyses. Several scoring systems (HCT-specific comorbidity indicator (HCT- CI)/ modified European Group for Blood and Gist Transplantation threat score (mEBMT)) have been espoused to prognosticate HCT issues in other hematologic malice. We retrospectively estimated HCT- CI and mEBMT to prognosticate nonrelapse mortality (NRM) in 824 ATL cases registered in the Japan Society for Hematopoietic Cell Transplantation TRUMP database, from 2008 until 2013. A advanced HCT- CI was associated with lesser NRM when comparing HCT- CI 0 versus HCT- CI 1 to 3 and HCT- CI 0 versus HCT- CI ≥ 4. An advanced mEBMT score wasn't associated with advanced NRM when comparing mEBMT 0 to 3 with 4 to 6. Because ATL cases are aged and accordingly at threat of fresh complications, we developed an optimized prognostic indicator for ATL (ATL- HCT- PI) using known threat factors age, HCT- CI, and patron – philanthropist coitus combination. The ATL- HCT- PI scores effectively prognosticated the 2- time NRM (22.0, 27.7, and44.4, independently). Thus, the recently developed ATL- HCT- PI, in combination with other threat factors, is more useful for prognosticating NRM in HCT for ATL cases.